# PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

> **NCT05743777** · PHASE2 · WITHDRAWN · sponsor: **Canadian Cancer Trials Group**

## Conditions studied

- Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** MET-4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05743777
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-12
- **Primary completion:** 2023-05-12
- **Final completion:** 2023-05-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company withdrew financial support
- **Last updated:** 2023-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743777, "PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05743777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*